EML4 and neoplasm: This patient’s tumor contained an EML4-ALK variant 3a fusion, which has been reported to be relatively resistant to targeted therapy compared to other ALK fusion variants [32], and failed to respond to both crizotinib and the second-generation ALK inhibitor, ceritinib.